TG Therapeutics
TGTX
90 hedge funds and large institutions have $396M invested in TG Therapeutics in 2015 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 47 increasing their positions, 21 reducing their positions, and 7 closing their positions.
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
124% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 21
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
19% more capital invested
Capital invested by funds: $332M → $396M (+$63.8M)
18% more call options, than puts
Call options by funds: $4.12M | Put options by funds: $3.5M
14% more funds holding
Funds holding: 79 → 90 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.72M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$6.23M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$5.32M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$2.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$12.2M |
| 2 |
BM
Bridger Management
New York
|
-$8.14M |
| 3 |
HH
HWG Holdings
Houston,
Texas
|
-$1.74M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.71M |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$1.2M |
TGTX Hedge Fund Activity: Q2 2015 in Review
90 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2015, worth a combined $396M — up 19% from $332M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TGTX positions and 7 closed out — a net gain of 11 holders — while 47 added to existing stakes and 21 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $12.9M. The largest seller was Visium Asset Management, cutting an estimated $12.2M.
- 90 institutional investors held TG Therapeutics (TGTX) as of Q2 2015, up from 79 in Q1 2015.
- Funds reported $396M of TG Therapeutics stock for Q2 2015, up 19% quarter-over-quarter.
- 18 funds opened new TG Therapeutics positions in Q2 2015 and 7 closed out, a net change of +11 holders.
- The largest TG Therapeutics buyer in Q2 2015 was Fidelity Investments, an estimated $12.9M added.
- The largest TG Therapeutics seller in Q2 2015 was Visium Asset Management, an estimated $12.2M sold.
Based on aggregated 13F filings for Q2 2015.